IP Library Granted Patent US 8,268,885
Granted Patent B2
US 8,268,885 · App. 10/571,325 · Granted Sep 18, 2012

Entry inhibitors of the HIV virus

Assignee: Janssen R&D Ireland
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,268,885
App. No.
10/571,325
Granted
Sep 18, 2012
Kind
B2
Abstract

The present invention relates to small molecules as entry inhibitors of the HIV virus, processes for their preparation as well as pharmaceutical compositions, their use as medicines, and diagnostic kits comprising them. The present invention also concerns combinations of the present entry inhibitors with other anti-retroviral agents. It further relates to their use in assays as reference compounds or as reagents. The compounds of the present invention are useful for preventing or treating infection by HIV and for treating AIDS.

Claims (1)

1. A compound selected from the group consisting of:

Assignments (2)
CHANGE OF NAME Recorded Aug 15, 2012
From: TIBOTEC PHARMACEUTICALS
To: JANSSEN R&D IRELAND
Reel/Frame 028794/0357 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 23, 2006
From: VAN ACKER, KOENRAAD LODEWIJK AUGUST; TAHRI, ABDELLAH; WIGERINCK, PIET TOM BERT PAUL; MICHIELS, LIEVE EMMA JAN
To: TIBOTEC PHARMACEUTICALS, LTD.
Reel/Frame 018158/0488 →
Priority Claims (1)
EP 03103362 · Sep 11, 2003 · regional
Continuity (2)
Provisional Application 60502476 · Sep 12, 2003
Related Publication 20070066623A1 · Mar 22, 2007